All In Biotech

Drug Trial Radar · NCT07681674

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product on a BicycleTx Limited-Sponsored Study

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

May 30, 2030

Study completion May 30, 2030

Sponsor

Lead sponsor
BicycleTx LimitedIndustry
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BiCAP-201 trial offers continued access to Bicycle investigational product treatments zelenectide pevedotin, nuzefatide pevedotin, and BT7480 for participants currently receiving and deriving clinical benefit from one of these treatments in a Bicycle Therapeutics-sponsored clinical trial. Bicycle Therapeutics will continue to monitor longer term safety of these treatments.

Conditions

  • Advanced Solid Tumors

Interventions

  • Zelenectide pevedotinDrug

    Participants will continue on the same treatment regimen they were receiving in their parent study.

  • BT7480Drug

    Participants will continue on the same treatment regimen they were receiving in their parent study.

  • Nuzefatide pevedotinDrug

    Participants will continue on the same treatment regimen they were receiving in their parent study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monitor safety for participants receiving a Bicycle investigational productTime frame: Up to 48 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.